ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 585,71
-0,62%
Dow Jones
40 211,72
0,53%
DAX
18 501,44
-0,53%
Brent Oil
83,73
-0,72%
Bitcoin
62 919,07
-2,98%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NYSE
  6. Teva Pharmaceutical Industries Ltd (TEVA)

  7. Teva Pharmaceutical Industries Ltd (TEVA) Actualités

TEVA

Teva Pharmaceutical Indu... (TEVA)

Teva Pharmaceutical Industries Ltd
De:
Trier par:
 Showing the most relevant articles for your search:NYSE:TEVA
DateHeureSourceTitreSymboleSociété
23/04/201814h30Business WireTeva to Report First Quarter 2018 Financial Results on May 3, 2018NYSE:TEVATeva Pharmaceutical Industries Ltd
19/04/201813h00Business WireTeva and the Procter & Gamble Company Have Agreed to Terminate the PGT Healthcare PartnershipNYSE:TEVATeva Pharmaceutical Industries Ltd
17/04/201814h00Business WireTeva to Present New Data Across Multiple Therapeutic Areas at 70th Annual Meeting of the American Academy of NeurologyNYSE:TEVATeva Pharmaceutical Industries Ltd
05/04/201808h49Dow Jones NewsIndivior Sues Companies for Suboxone Copyright InfringementNYSE:TEVATeva Pharmaceutical Industries Ltd
26/03/201820h49Business WireTeva Announces the Launch of a Generic Version of Lialda® in the United StatesNYSE:TEVATeva Pharmaceutical Industries Ltd
23/03/201818h27Business WireTeva Announces the Launch of a Generic Version of ALOXI® in the United StatesNYSE:TEVATeva Pharmaceutical Industries Ltd
12/03/201813h40Business WireTeva to Present at the Cowen & Company 38th Annual Healthcare ConferenceNYSE:TEVATeva Pharmaceutical Industries Ltd
07/03/201822h14Business WireTeva Announces Upsizing and Successful Pricing of $4.5 Billion of Senior NotesNYSE:TEVATeva Pharmaceutical Industries Ltd
28/02/201815h00Business WireTeva Announces Launch of Offering of Senior NotesNYSE:TEVATeva Pharmaceutical Industries Ltd
20/02/201817h03Business WireTeva Announces Exclusive Launch of Two Strengths of a Generic Version of Solodyn® in the United StatesNYSE:TEVATeva Pharmaceutical Industries Ltd
16/02/201817h39Business WireTeva Announces U.S. Launch of QVAR® RediHaler™ (Beclomethasone Dipropionate HFA) Inhalation AerosolNYSE:TEVATeva Pharmaceutical Industries Ltd
09/02/201815h00Business WireTeva Announces Launch of a Generic Version of Syprine® in the United StatesNYSE:TEVATeva Pharmaceutical Industries Ltd
09/02/201809h02Dow Jones NewsTeva Sustains $11.6 Billion Loss -- WSJNYSE:TEVATeva Pharmaceutical Industries Ltd
08/02/201820h24Dow Jones NewsTeva Pharmaceutical Shares Plunge After Quarterly Loss and 2018 Outlook WarningNYSE:TEVATeva Pharmaceutical Industries Ltd
08/02/201813h00Business WireTeva Reports 2017 Full Year and Fourth Quarter Financial ResultsNYSE:TEVATeva Pharmaceutical Industries Ltd
02/02/201813h00Business WireEuropean Medicines Agency (EMA) Accepts Fremanezumab Marketing Authorization ApplicationNYSE:TEVATeva Pharmaceutical Industries Ltd
01/02/201814h26Business WireTeva Completes Amendment to Credit FacilitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
01/02/201813h00Business WireTeva Announces Completion of Global Women’s Health Divestiture to CVC Capital PartnersNYSE:TEVATeva Pharmaceutical Industries Ltd
25/01/201819h00Business WireTeva to Host Conference Call to Discuss Fourth Quarter and Full Year 2017 Financial Results at 8 a.m. ET on February 8, 2018NYSE:TEVATeva Pharmaceutical Industries Ltd
22/01/201814h00Business WireTeva Announces Top-Line Results from Phase III Studies of Subcutaneously Administered Reslizumab in Patients with Severe Eosi...NYSE:TEVATeva Pharmaceutical Industries Ltd
15/01/201814h00Business WireTeva Announces U.S. FDA Approval of TRISENOX® (arsenic trioxide) Injection for First Line Treatment of Acute Promyelocytic L...NYSE:TEVATeva Pharmaceutical Industries Ltd
12/01/201809h02Dow Jones NewsOhio Talks Settlement Of Opioid Lawsuits -- WSJNYSE:TEVATeva Pharmaceutical Industries Ltd
12/01/201800h00Dow Jones NewsADRs End Slightly Higher; Teva, Ryanair, SAP Trade ActivelyNYSE:TEVATeva Pharmaceutical Industries Ltd
11/01/201823h20Dow Jones NewsOhio Takes Steps Toward Resolution of Opioid LitigationNYSE:TEVATeva Pharmaceutical Industries Ltd
11/01/201820h52Dow Jones NewsOhio in Talks to Settle Opioid Suit, State Attorney General SaysNYSE:TEVATeva Pharmaceutical Industries Ltd
08/01/201814h00Business WireTeva Announces Global License Agreement with Alder BioPharmaceuticals® in the Field of Anti-CGRP-Based TherapyNYSE:TEVATeva Pharmaceutical Industries Ltd
04/01/201817h12Business WireTeva to Present at the 36th Annual J.P. Morgan Healthcare ConferenceNYSE:TEVATeva Pharmaceutical Industries Ltd
02/01/201820h25Business WireTeva Announces Launch of an Authorized Generic of Estrace® Cream in the United StatesNYSE:TEVATeva Pharmaceutical Industries Ltd
27/12/201715h00Business WireTeva Announces Exclusive Launch of a Generic Version of Reyataz® in the United StatesNYSE:TEVATeva Pharmaceutical Industries Ltd
18/12/201714h00Business WireFDA Accepts Biologics License Application for Fremanezumab with Priority Review for Prevention of Migraine & Grants Fast Trac...NYSE:TEVATeva Pharmaceutical Industries Ltd
 Showing the most relevant articles for your search:NYSE:TEVA

Dernières Valeurs Consultées

EU
AF
Air FranceKLM
EU
PX1
CAC 40
EU
GLE
Societe Generale
EU
RNO
Renault
EU
SGO
Cie de SaintGobain
EU
CS
Axa
EU
CAP
Capgemini
NYSE
MCD
McDonalds
EU
ML
Michelin
EU
MC
Lvmh Moet Hennessy Louis...
EU
DG
Vinci
EU
PX4
SBF 120
EU
VIV
Vivendi
EU
ACA
Credit Agricole
FTSE
UKX
FTSE 100
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés